Hepion Pharmaceuticals Investor Relations Material
Latest events
Q2 2025
14 Aug, 2025
Q4 2024
8 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Hepion Pharmaceuticals Inc
Access all reports
Hepion Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for liver diseases, particularly non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company’s lead drug candidate, based on cyclophilin inhibition technology, aims to target inflammation, fibrosis, and viral infections affecting the liver. The company is headquartered in Edison, New Jersey, and its shares are listed on the NASDAQ.
)
)
)